Howard Hughes Medical Institute8y
New study suggests why mice with cystic fibrosis mutations can stave off bacterial infections in their lungs.
New study suggests why mice with cystic fibrosis mutations can stave off bacterial infections in their lungs. People who have cystic fibrosis are susceptible to bacterial infections in their lungs.
Nature2y
Laboratory standards and guidelines for population-based cystic fibrosis carrier screening
In 1997, the National Institutes of Health convened a Consensus Development Conference on Cystic Fibrosis (CF). 1 The Consensus Conference recommended that genetic screening for CF mutations ...
clinicaladvisor.com26d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
An additional 94 non-F508del CFTR mutations and a boxed warning on liver ... 711+3A→G, E831X, 5T;TG12, 5T;TG13, 296+28A→G, 621+3A→G, 1898+3A→G, 2789+ 2insA, 3850-3T→G, 3600G→A, 3849+4A ...
Kaleido Scope8y
Cystic Fibrosis
Eric Sorscher and colleagues at UAB developed two different ways to overcome the genetic mutations responsible for cystic fibrosis. Cystic fibrosis is a hereditary disease caused by mutations in a ...
Healio5d
Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Business Wire1mon
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
The following 94 mutations have been added to the TRIKAFTA ® label for the first time: TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have ...